Add time:08/15/2019 Source:sciencedirect.com
Clofazimine (CFZ) is a promising candidate drug for use in the management of multidrug-resistant tuberculosis (MDR-TB) patients. In this study, the minimum inhibitory concentration (MIC) method and checkerboard method were used to investigate potential synergies between CFZ and moxifloxacin (MOX) or CAPREOMYCIN (cas 11003-38-6) (CAP). 30 Mycobacterium tuberculosis strains were collected, including 13 MDR strains, 2 extensive drug- resistant (XDR) strains, 3 pan-sensitive strains and 12 strains resistant to other drugs. When the minimum fractional inhibitory concentration indexes (FICIs) were calculated, synergy was found in 21 (70.00%) M. tuberculosis strains against the CFZ/CAP combination and 29 (96.67%) against the CFZ/MOX combination. When the maximum FICIs were calculated, 10 out of 15 MDR/XDR strains and 2 out of 15 other drug-resistant or pan-sensitive strains showed antagonism against the CFZ/CAP combination, whilst 8 out of 15 MDR/XDR strains and 1 out of 15 other drug-resistant or pan-sensitive strains showed antagonism against the CFZ/MOX combination, respectively. In conclusion, these findings demonstrate that the combination of CFZ and MOX shows better synergism than the combination of CFZ and CAP. The MDR/XDR isolates are more likely to show antagonism than the other drug-resistant or pan-sensitive strains in both CFZ/MOX and CFZ/CAP combinations. Taken together, we suggest that CFZ, in combination with MOX, may be a promising drug regimen for the treatment of MDR-TB, especially for the susceptible M. tuberculosis infectious.
We also recommend Trading Suppliers and Manufacturers of CAPREOMYCIN (cas 11003-38-6). Pls Click Website Link as below: cas 11003-38-6 suppliers
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View